KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Charles River Laboratories International (CRL) Revenue (2016 - 2025)

Charles River Laboratories International has reported Revenue over the past 17 years, most recently at $994.2 million for Q4 2025.

  • For Q4 2025, Revenue fell 0.83% year-over-year to $994.2 million; the TTM value through Dec 2025 reached $4.0 billion, down 0.85%, while the annual FY2025 figure was $4.0 billion, 0.85% down from the prior year.
  • Revenue for Q4 2025 was $994.2 million at Charles River Laboratories International, down from $1.0 billion in the prior quarter.
  • Over five years, Revenue peaked at $1.1 billion in Q4 2022 and troughed at $824.6 million in Q1 2021.
  • A 5-year average of $985.6 million and a median of $1.0 billion in 2024 define the central range for Revenue.
  • Biggest five-year swings in Revenue: surged 33.99% in 2021 and later decreased 7.85% in 2023.
  • Year by year, Revenue stood at $905.0 million in 2021, then rose by 21.52% to $1.1 billion in 2022, then decreased by 7.85% to $1.0 billion in 2023, then fell by 1.08% to $1.0 billion in 2024, then fell by 0.83% to $994.2 million in 2025.
  • Business Quant data shows Revenue for CRL at $994.2 million in Q4 2025, $1.0 billion in Q3 2025, and $1.0 billion in Q2 2025.